The company plans to launch the injectable version of Semaglutide in a number of countries, starting with Canada in January 2026. India and Brazil will follow
Tariffs pose a near-term risk. However, Zydus’s focus on novel drugs and the foray into medical devices are key moves to watch
The medium-term growth drivers include the global rollout of respiratory and GLP-1 drugs.
In times to come, the company may gear up for new inorganic initiatives to improve its market share in India. In the meantime, margins may moderate
Under the agreement, Biocon will handle the development, manufacturing, and supply of the diabetes management drug, while Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
The availability of the drug in India may cause a major disruption in the Indian diabetes care drugs market which is expected to register a CAGR greater than 3.5 percent between 2022 and 2027. The COVID-19 pandemic has contributed a major increase in the market.
Danish pharma giant working on launching Icodec. India managing director and corporate vice-president Vikrant Shrotriya says the company also has a plan to launch anti-obesity drug, Wegovy, in India but it may not happen very soon.
Tesla and Twitter owner Elon Musk is the latest celebrity to admit using Wegovy, a higher dose version of Ozempic, for keeping his body "fit, ripped, and healthy”. The drug has caused quite a stir among celebs and influencers over the last several months
Patients with obesity issues may have found a magical drug that will keep them free from grave consequences. A drug named semaglutide suppresses appetite in its fight against obesity and is likely to cut down body weight by 20%.